XDH and diabetic kidney disease: To finally confirm the therapeutic role of XOR inhibition in DKD, further well-designed in vivo experiments and clinical trials may be needed to explore whether febuxostat acts on the renoprotective effects of reducing ROS through these signaling pathways.